

Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

By Gordon J. Freeman,^{*} Andrew J. Long,[‡] Yoshiko Iwai,[§] Karen Bourque,[‡] Tatyana Chernova,^{*} Hiroyuki Nishimura,[§] Lori J. Fitz,[‡] Nelly Malenkovich,^{*} Taku Okazaki,[§] Michael C. Byrne,[‡] Heidi F. Horton,[‡] Lynette Fouser,[‡] Laura Carter,[‡] Vincent Ling,[‡] Michael R. Bowman,[‡] Beatriz M. Carreno,[‡] Mary Collins,[‡] Clive R. Wood,[‡] and Tasuku Honjo[§]

From the ^{*}Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115; the [‡]Genetics Institute, Wyeth-Ayerst Research, Cambridge, Massachusetts 02140; and the [§]Department of Medical Chemistry, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan

Abstract

PD-1 is an immunoinhibitory receptor expressed by activated T cells, B cells, and myeloid cells. Mice deficient in *PD-1* exhibit a breakdown of peripheral tolerance and demonstrate multiple autoimmune features. We report here that the ligand of *PD-1* (*PD-L1*) is a member of the B7 gene family. Engagement of *PD-1* by *PD-L1* leads to the inhibition of T cell receptor-mediated lymphocyte proliferation and cytokine secretion. In addition, *PD-1* signaling can inhibit at least suboptimal levels of CD28-mediated costimulation. *PD-L1* is expressed by antigen-presenting cells, including human peripheral blood monocytes stimulated with interferon γ , and activated human and murine dendritic cells. In addition, *PD-L1* is expressed in nonlymphoid tissues such as heart and lung. The relative levels of inhibitory *PD-L1* and costimulatory B7-1/B7-2 signals on antigen-presenting cells may determine the extent of T cell activation and consequently the threshold between tolerance and autoimmunity. *PD-L1* expression on nonlymphoid tissues and its potential interaction with *PD-1* may subsequently determine the extent of immune responses at sites of inflammation.

Key words: binding • proliferation inhibition • cytokine secretion inhibition • tissue expression • peripheral tolerance

Introduction

The balance of positive and negative signals is of central importance in maximizing the ability of the adaptive immune response to defend the host while maintaining immunologic tolerance and preventing autoimmunity. PD-1 is a type I transmembrane protein that is transcriptionally induced in activated T cells, B cells (1–3), and myeloid cells (Nishimura, H., and T. Honjo, unpublished data). The extracellular region of PD-1 consists of a single Ig-like vari-

able (IgV)¹ domain (4), and the cytoplasmic region contains an immunoreceptor tyrosine-based inhibitory motif (for a review, see reference 5). Recent work has revealed that the PD-1 receptor acts to downregulate immune responses and its loss leads to a breakdown of peripheral tolerance. Mice deficient in *PD-1* develop lupus-like proliferative arthritis and glomerulonephritis with predominant IgG3 deposition as they age (6). Additionally, in a manner similar to that reported in the lupus-prone MRL mice, introduction of the *lpr* mutation leads to accelerated disease onset and severity

G.J. Freeman, A.J. Long, and Y. Iwai contributed equally to this work. C.R. Wood and T. Honjo share senior authorship.

Address correspondence to Tasuku Honjo, Department of Medical Chemistry, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan. Phone: 81-75-753-4371; Fax: 81-75-753-4388; E-mail: honjo@mfour.med.kyoto-u.ac.jp

¹Abbreviations used in this paper: CHO, Chinese hamster ovary; CTLA-4, CTL-associated antigen 4; EST, expressed sequence tag; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ICOS, inducible costimulator; IgV, Ig-like variable; PD-L1, PD-1 ligand 1.

of symptoms. Furthermore, 2C-TCR (anti-H-2L^d) transgenic mice homozygous for the *PD-1* null mutation in the autoreactive H-2^{b/d} background develop a chronic graft-versus-host-like disease (6). In this model, peripheral 2C T cells show a memory rather than a naive phenotype and infiltrate into tissues including the epidermis, despite efficient negative selection in the thymus. However, it remains to be determined whether this regulation is achieved at the activation phase (lymph nodes), at the effector phase (tissues), or both. Direct approaches to this question as well as further characterization of this inhibitory pathway have been hampered by a lack of knowledge of the identity of the ligand for PD-1.

PD-1 is structurally similar to CTL-associated antigen 4 (*CTLA-4*), which binds B7-1 and B7-2 and plays a crucial role for the maintenance of T cell homeostasis (for reviews, see references 7 and 8). Although PD-1 does not have the MYPPPY motif that is critical for B7-1 and B7-2 binding, the extracellular regions of PD-1 and CTLA-4 each consist of a single IgV domain, with 23% identity to each other. This is in comparison to the ~30% identity between CTLA-4 and CD28 (9). Thus, we reasoned that the ligand of PD-1 might be structurally related to B7-1 and B7-2. We have pursued this hypothesis by searching for B7-like molecules and testing their binding to PD-1. In this work, we identify a ligand of PD-1 and demonstrate that this receptor–ligand interaction leads to the inhibition of lymphocyte proliferation.

Materials and Methods

Molecular Cloning. A BLAST search of the human expressed sequence tag (EST) database of the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov>) identified two overlapping ESTs with homology to *B7-1* and *B7-2* (AA292201 and AA399416). A 389-bp portion of the cDNA was amplified by PCR using as primers 5'-dCAGCTATGGTGGT-GCCGACTACAA-3' and 5'-dAGGTGCTAGGGGACAGT-GTTAGACA-3'. The PCR product was biotin labeled and used to isolate a full-length cDNA by Cloncapture (CLONTECH Laboratories, Inc.) from a human placenta cDNA library in the pAXEF vector (10). A search of the National Center for Biotechnology Information murine EST database identified overlapping sequences with homology to human PD-1 ligand 1 (*PD-L1*; AA896104 and AA823166). A 409-bp portion was amplified by PCR using as primers 5'-dGAGAGCCTCGCGTCCAAAG-3' and 5'-dGTGGTTTTGCCCTGGCTGTGATCT-3'. The PCR product was biotin labeled and used to isolate a full-length cDNA by Cloncapture (CLONTECH Laboratories, Inc.) from a murine-activated T cell cDNA library in the pAXEF vector.

Fusion Proteins and Cell Transfections. The Ig fusion proteins used consist of the complete extracellular region of a receptor linked to the hinge-C_{H2}-C_{H3} domains of either human Igγ1 or the same domains of murine Igγ2a (with four point mutations blocking Fc receptor and complement binding) to give Ig(γ1) and Ig(γ2a) fusions, respectively (11). These recombinant proteins were produced in COS cells transiently transfected with LipofectAMINE (GIBCO BRL) or stably transfected Chinese hamster ovary (CHO) cell lines and purified from conditioned media using protein A-Sepharose.

The human *PD-L1* cDNA was subcloned into pEF6 (Invitrogen) and linearized with ScaI. This DNA was coelectroporated into CHO-K1 cells with a plasmid construct containing a hygromycin B resistance gene under the control of a phosphoglycerate kinase gene promoter. Cells were selected in 800 μg/ml hygromycin B and cloned by limiting dilution. The murine *PD-L1* cDNA in pAXEF was linearized with ApaI and coelectroporated into CHO-K1 cells with a puromycin resistance gene under the control of a phosphoglycerate kinase gene promoter. Cells were selected in 10 μg/ml puromycin and cloned by limiting dilution.

Murine T Cell Assays. Splenic T cells were collected by anti-IgM panning from pools of splenocytes from two to three age-matched C57BL/6 and C57BL/6-*PD-1*^{-/-} mice, resulting in 80% purity. 4 × 10⁴ cells/well in 96 U-bottomed plates (Iwaki) were incubated with the indicated concentrations of reagents. Purified anti-mouse CD3 (145-2C11) alone or in combination with hPD-L.Ig(γ2a) or mouse IgG2a were precoated overnight at 4°C. Cells were cultured for 72 h, then pulsed with 0.5 μCi of [³H]thymidine (Amersham Pharmacia Biotech) per well for the last 18 h, and incorporated label was measured.

Human T Cell Proliferation and Cytokine Assays. PBMCs were isolated by Ficoll-Hypaque gradient centrifugation. CD4⁺ T cell populations (85–90% purity) were purified by negative selection using a cocktail of mAbs and immunomagnetic beads (PerSeptive Biosystems). Anti-CD3, control IgG, and fusion protein were covalently attached to polyurethane-coated tosyl-activated Dynabeads (Dyna) according to the manufacturer's instructions and as described previously (12). Anti-CD3 Ab (UCHT1; BD Pharmingen) at the indicated concentration was added to 10⁷ beads/ml in 0.1 M phosphate buffer, pH 7.4. Control IgG was added to the bead suspension in order to maintain a constant total Ig concentration of 5 μg/ml during binding. Similarly, anti-CD3/hPD-L.Ig(γ2a) beads were prepared with the indicated anti-CD3 Ab concentration, a constant concentration of either hPD-L1.Ig representing 40% of the total bound protein (2 μg/10⁷ beads), or control IgG to make up the remaining total bound protein. 10⁵ T cells were cultured in 96-well flat-bottomed plates, and beads were added at a 1:1 bead/cell ratio in the presence or absence of the indicated concentrations of anti-CD28 Ab (CD28.2; BD Pharmingen). Proliferation was determined by labeling cultures for the last 6 h of a 4-d assay with 1 μCi [³H]thymidine/well. For analysis by cytokine ELISAs, cultures were set up as described above and supernatants were harvested at the indicated times. IFN-γ, IL-10, and IL-2 concentrations were determined using commercially available ELISA kits (Genzyme).

Dendritic Cell Isolation. Human dendritic cells were derived from peripheral blood. Mononuclear cells were isolated after fractionation on a Ficoll gradient. Nonadherent cells were removed and the remaining cells were cultured in 150 ng/ml human GM-CSF (R & D Systems) and 100 ng/ml human IL-4 (R & D Systems) for 2 d. The nonadherent dendritic cells were isolated (CD80⁺CD86⁺HLA-DR⁺CD54⁺CD58⁺CD1a⁺) and cultured in GM-CSF alone or activated with GM-CSF, 2.5 μg/ml LPS (Sigma-Aldrich), and 10 ng/ml human IFN-γ. At 4 and 20 h after activation, cells were harvested and RNA was isolated using the RNeasy kit (QIAGEN).

Murine bone marrow mononuclear cells were immunodepleted of granulocytes, lymphocytes, and Ia⁺ cells by magnetic-activated cell sorting and cultured in petri dishes with GM-CSF and IL-4. Dendritic cells were harvested as the nonadherent population after 7 d of culture, and demonstrated to be 75–80% CD11c⁺, high Ia⁺ cells. Cells were activated with LPS and human IFN-γ.




Figure 2. The binding of PD-1 to PD-L1. (A) CHO cells stably transfected with human or murine *PD-L1* or vector alone were stained with hPD-1.Ig(γ 2a), mPD-1.Ig(γ 1), hCTLA-4.Ig(γ 2a), hCD28.Ig(γ 1), or hICOS.Ig(γ 2a) (species matched), and developed with goat anti-murine IgG2a-PE or anti-human IgG-FITC antisera. (B) PD-L1.Ig was tested for binding to immobilized mPD-1.Ig(γ 1) (gray bars), hPD-1.Ig(γ 1) (black bars), and hCTLA-4.Ig(γ 1) (white bars) using surface plasmon resonance on a BIAcore 2000 instrument. Receptor-Fc fusion proteins were immobilized on a CM5 dextran chip by amine coupling with normal human serum/*N*-ethyl-*N'*-(dimethylamino)propyl I carbodiimide hydrochloride (EDC) in 10 mM sodium acetate, pH 4.0, as described (reference 27). The amounts of protein immobilized were 5,383 response units (RU) for mPD-1.Ig(γ 1), 5,416 RU for hPD-1.Ig(γ 1), and 11,493 RU for hCTLA-4.Ig(γ 1). Concentrated COS-conditioned medium from hPD-L1.Ig(γ 2a)-transfected cells was analyzed with (+) or without (-) coinjection of 100 μ g/ml of soluble mPD-1.Ig, hPD-1.Ig, or hCTLA-4.Ig for competition. Binding was quantified as an increase in RU at 60 s after the end of injection compared with a baseline established 20 s before injection.

man B7-1 and B7-2 did not bind immobilized human PD-1.Ig (data not shown).

PD-L1, B7-1, and B7-2 Are Coexpressed on Antigen-presenting Cells. We next examined the pattern of *PD-L1* expression on antigen-presenting cells and compared it with that of *B7-1* and *B7-2* expression. First, we analyzed expression in human blood monocytes by RNA blot hybridization and found that *PD-L1* is not expressed by unstimulated monocytes, but is rapidly upregulated upon IFN- γ treatment (Fig. 3 A). Treatment of monocytes with another proinflammatory cytokine, TNF- α , led to a low level induction similar to that found with medium alone, presumably as a result of activation by adherence to plastic (Fig. 3 A). In addition to the major 4.2-kb *PD-L1* mRNA, we also observed a minor 1.8-kb *PD-L1* mRNA species in IFN- γ -treated monocytes. The major 4.2-kb mRNA species has also been reported by Dong et al. (16). We also detected expression of *PD-L1* by human B cells activated by cell surface Ig cross-linking, but not by the Raji cell line (Fig. 3 A). Similarly, *B7-1* is not expressed by unstimulated monocytes but is upregulated in response to IFN- γ with similar kinetics to *PD-L1* expression. In contrast, *B7-2* mRNA is constitutively expressed in monocytes and levels are unaffected by IFN- γ or TNF- α .

Second, *PD-L1, B7-1, and B7-2* mRNA expression by human dendritic cells was examined by quantitative PCR. Human peripheral blood-derived dendritic cells were treated with GM-CSF alone or activated with GM-CSF, LPS, and IFN- γ . As a result of activation by LPS and IFN- γ , *PD-L1* mRNA was rapidly induced with a 16-fold increase at 4 h and a 34-fold increase at 20 h relative to non-induced cells (Fig. 3 B). *B7-1* and *B7-2* mRNAs were also induced upon activation: *B7-1* was induced 21-fold at 4 h and 22-fold at 20 h. *B7-2* showed little induction at 4 h;

however, expression was induced fivefold at 20 h (Fig. 3 B). Expression of *PD-L1* by murine bone marrow-derived dendritic cells treated with LPS and IFN- γ was examined using GeneChip[®] hybridization. *PD-L1* expression in these cells follows a pattern similar to that observed on human dendritic cells: a fivefold induction of the *PD-L1* mRNA relative to the uninduced cells at 6 and 20 h after induction (data not shown). These data demonstrate that *PD-L1* is expressed by antigen-presenting cells and lymphocytes, and it is induced on dendritic cells in a manner similar to *B7-1* and *B7-2*. We also demonstrated an induction of *PD-L1* by treatment of human keratinocytes with phorbol ester and IFN- γ (Fig. 3 C).

In murine tissues, we found an \sim 3.7-kb *PD-L1* mRNA transcript by Northern blot hybridization. Dong et al. (16) have reported a 4.2-kb *PD-L1 (B7-H1)* mRNA species in normal human tissue RNA. The distribution of the murine *PD-L1* mRNA closely resembled that of the human with high levels in the heart, thymus, and lung, and low levels in the kidney, spleen, and liver (Fig. 3 D).

By PCR of monochromosomal human somatic cell hybrids, we demonstrated that the human *PD-L1* gene is located on chromosome 9 (Fig. 3 E), unlike the *B7-1* and *B7-2* genes, which are clustered on chromosome 3 (19). Thus, the parallel upregulation we observe for these genes on activated dendritic cells is not the result of clustering at a single chromosomal site. In addition, this also distinguishes *PD-L1* from the B7-like butyrophilins, which are in the MHC gene complex of human chromosome 6 (20).

PD-1-PD-L1 Interaction Inhibits CD3-mediated T Cell Proliferation. To examine the functional significance of the PD-1-PD-L1 interaction, we compared the effect of PD-L1.Ig on the proliferation of murine T cells derived from wild-type and *PD-1*-deficient mice (21). We first exam-




Figure 3. Expression of *PD-L1* in antigen-presenting cells and murine tissues. (A) Northern blot analysis of total RNA of human peripheral blood monocytes stimulated with 500 U/ml human IFN- γ , 100 U/ml human TNF- α , or media alone, and anti-Ig-activated human B cells, with human *PD-L1*, *B7-1*, *B7-2*, and β -actin cDNA probes. Cells were prepared and stimulated as described (reference 28). Act.B, actinomycin B. (B) Isolated human peripheral blood dendritic cells (DC) were cultured in either human GM-CSF alone (gray bars) or in GM-CSF, LPS, and IFN- γ (black bars) for 4 or 20 h, after which RNA was isolated for quantitative (real time) PCR analysis. Fluorescence is plotted as a ratio of *PD-L1*, *B7-1*, or *B7-2* signal to the GAPDH signal. (C) Northern blot analysis of human keratinocyte total RNA with a human *PD-L1* cDNA probe. Keratinocytes were isolated and activated with PMA and IFN- γ , as described previously (reference 10). (D) Northern blot analysis of murine tissue polyA⁺ RNAs (Ambion) with a murine *PD-L1* cDNA probe. (E) The human *PD-L1* gene was amplified by PCR from monochromosomal somatic cell hybrid genomic DNAs containing the indicated human chromosome as well as hamster, murine, and human genomic DNAs.

ined the proliferation of purified splenic T cells from wild-type and *PD-1*^{-/-} mice to anti-CD3 mAb and found they were essentially identical (Fig. 4 A). Thus, the loss of *PD-1* did not impair the ability of T cells to respond to stimulation through the TCR, nor did it confer a hyperproliferative phenotype in a primary stimulation. To examine the effects of *PD-L1*, an optimal concentration of anti-CD3 mAb and varying concentrations of human PD-L1.Ig or an IgG control were precoated on plastic plates. Proliferation of purified splenic T cells was measured 3 d after stimulation by incorporation of [³H]thymidine. As shown in Fig. 4 B, human PD-L1.Ig inhibited proliferation of *PD-1*^{+/+} T cells in a dose-dependent fashion relative to the IgG control (Fig. 4 B). In contrast, human PD-L1.Ig had no effect on the proliferation of *PD-1*^{-/-} T cells under the same condi-

tions. These results show that *PD-L1* can attenuate TCR-mediated T cell proliferation. Furthermore, the failure of PD-L1 to inhibit *PD-1*-deficient T cells indicates that PD-L1 conveys this signal via its interaction with PD-1.

The functional consequences of PD-L1 interaction with its receptor were also examined using human T cells. Purified CD4⁺ T cells obtained from PBMCs were activated with beads coated with anti-CD3 mAb and either human PD-L1.Ig or a control Ig. Proliferation and cytokine production were assessed 96 h after stimulation. As shown in Fig. 4 C, cells activated with anti-CD3 mAb/PD-L1.Ig-coated beads showed a 69% decrease in proliferation relative to anti-CD3 mAb/control Ig-activated cells. Furthermore, activation of cells in the presence of PD-L1 also impairs cytokine secretion. In the presence of PD-L1, the




Figure 4. TCR activation of murine and human T cells in the presence of *PD-L1* results in inhibition of T cell proliferation and cytokine production. (A) Splenic T cells from wild-type (open squares) and *PD-1*^{-/-} (filled circles) C57BL/6 mice were stimulated for 72 h with varying concentrations of pre-coated anti-CD3 Ab. (B) Splenic T cells from wild-type (squares) and *PD-1*^{-/-} (circles) C57BL/6 mice were stimulated for 72 h with 10 µg/ml of anti-CD3 mAb in combination with varying concentrations of hPD-L.Ig(γ2a) (filled symbols) or control mIgG2a (open symbols). [³H]Thymidine incorporation was measured in triplicate. These data are representative of four separate experiments. (C) Purified human CD4⁺ T cells were stimulated for 4 d with anti-CD3 mAb/control IgG-coated beads (stippled bars), anti-CD3 mAb/hPD-L.Ig(γ2a)-coated beads (hatched bars), or medium alone (black bars). The bead/cell ratio was 1:1. Proliferation was determined by [³H]thymidine incorporation in triplicate wells. Supernatants were collected at 96 h after activation, and cytokine concentrations were measured using commercially available ELISA kits. The data are representative of two separate experiments.

secretion of IFN-γ and IL-10 is decreased by ~80 and 60%, respectively (Fig. 4 C). IL-2 production was below detection under these activation conditions at both 24 and 96 h. However, under conditions in which costimulation in the form of soluble anti-CD28 is provided, activation of cells in the presence of PD-L1 also leads to a decrease in IL-2 production (data not shown). Thus, activation of murine and human T cells in the presence of PD-L1 leads to inhibition of both proliferation and cytokine secretion.

The Outcome of PD-1–PD-L1 Interaction Depends on the Strength of TCR and CD28 Signals. To examine the relationship between TCR-, CD28-, and PD-1-mediated signals, human CD4⁺ T cells were stimulated with suboptimal or optimal concentrations of anti-CD3 mAb, a fixed concentration of PD-L1.Ig, and increasing concentrations of soluble anti-CD28 mAb. Using anti-CD3 mAb-coated beads, the concentrations required for suboptimal and optimal T cell stimulation were established (data not shown). Under conditions of suboptimal TCR engagement (anti-CD3 mAb at 1 µg/ml), minimal proliferation is observed in the absence of costimulation (Fig. 5 A). The addition of increasing concentrations of soluble anti-CD28 mAb leads to an up to 30-fold increase in proliferation. Under these conditions, activation of T cells in the presence of PD-L1 results in an 80% reduction in proliferation (Fig. 5 A). A

maximal level of costimulation (anti-CD28 at 250 ng/ml) was required to rescue the inhibition of proliferation mediated by PD-L1 stimulation. In contrast, under saturating conditions of TCR activation (anti-CD3 mAb at 2 µg/ml), PD-L1-mediated inhibition of T cell proliferation is only observed in the absence of CD28 costimulation (Fig. 5 B).

Discussion

Recent studies of *PD-1*-deficient mice have revealed a critical immunoregulatory role for this receptor, as its absence leads to autoimmunity. As *PD-1* is structurally similar to *CTLA-4*, we hypothesized that the ligand of *PD-1* might be a member of the B7 gene family and searched for novel B7 homologues. One of these, later termed *PD-L1*, was found to bind *PD-1* specifically. The functional significance of this interaction has been demonstrated in T cell assays, in which engagement of *PD-1* by *PD-L1* leads to the inhibition of TCR-mediated lymphocyte proliferation and cytokine secretion. *PD-1* is also expressed by B cells and myeloid cells, and the significance of *PD-1* in these cell types is evidenced by the autoantibody generation and myeloid hyperplasia of *PD-1*-deficient mice (6, 21). Thus, *PD-L1* is expected to act on a wider range of cell types than we have demonstrated in this report.




Figure 5. TCR/*PD-L1* activation in the presence of CD28 costimulation results in inhibition of T cell proliferation. Purified human CD4⁺ cells were stimulated for 4 d with anti-CD3 mAb/control mIgG-coated beads (gray bars), or anti-CD3 mAb/hPD-L1.Ig(γ2a)-coated beads (black bars) in the presence of various concentrations of soluble anti-CD28 mAb. Stimulations were performed at (A) suboptimal (1 µg/ml) and (B) optimal (2 µg/ml) concentrations of anti-CD3 Ab. The bead/cell ratio was 1:1. Proliferation was determined by [³H]thymidine incorporation in triplicate wells. The data are representative of two separate experiments.

We have demonstrated that PD-L1 signaling can inhibit the TCR-mediated proliferation of T cells. The capacity of the PD-1–PD-L1 interaction to downregulate a CD3/CD28-stimulated response shows that PD-1 engagement results in the delivery of a strong inhibitory signal. However, the functional consequences of the PD-1–PD-L1 interaction are dependent on the relative strength of signals delivered via the TCR and CD28. Increasing levels of TCR or CD28 signaling can circumvent the inhibitory effects of PD-1 ligation at the activation stage. In the absence of the PD-1–PD-L1 interaction, the threshold of TCR signal needed for T cell activation will be lowered, consistent with the autoimmune reactions seen in *PD-1*-deficient mice (6).

In our experiments, inhibition was observed when PD-L1 was coimmobilized with anti-CD3. This would allow for coligation of the TCR and PD-1, consistent with the immunoreceptor tyrosine-based inhibitory motif of PD-1 delivering a negative signal by recruitment of an Src homology 2 (SH2) domain-containing tyrosine phosphatase. Indeed, using the A20II1.6 B lymphoma line, we have demonstrated that cocross-linking of the B cell receptor and PD-1 reduces the calcium influx observed by crosslinking of the B cell receptor alone, and leads to interaction of the cytoplasmic region of PD-1 with SHP-2 (our unpublished data). In addition, there is inhibition of the tyrosine phosphorylation of a variety of signaling molecules leading to suppression of the proliferative response.

Dong et al. (16) have shown an increase in T cell proliferation and IL-10 secretion by T cells stimulated with PD-L1/B7-H1 and low levels of anti-CD3. Previous work has demonstrated that *PD-1* expression is not constitutive but induced by antigen receptor cross-linking (2, 3). Thus, *PD-1* would be expected to be expressed and capable of interacting with PD-L1 in our assays in which the T cells are stimulated with higher levels of anti-CD3. It is unclear whether the PD-L1/B7-H1 costimulation reported by Dong et al. (16) is PD-1 dependent or whether it could be mediated by an alternative receptor for PD-L1. If a second, costimulatory receptor exists for PD-L1, this situation would parallel that of the costimulatory/inhibitory CD28/CTLA-4 receptor–B7-1/B7-2 ligand pairs. We do not find that PD-L1 induces IL-10 secretion in our assays. It should be noted that Dong et al. find that neutralizing Ab against IL-2 blocks the B7-H1-mediated increase in IL-10 production, suggesting that the IL-10 production is IL-2 dependent (16). Thus, the increase in IL-10 secretion may be due to the amplification of a population of cells rather than a direct induction.

The *PD-1* gene resembles that of *CTLA-4* in that it is expressed only after T cell activation. Thus, we expect that the PD-1–PD-L1 interaction may be most important in setting the TCR threshold requirements at sites of restimulation. Previously activated T cells that migrate to the periphery may reencounter antigen on cells expressing *PD-L1* but little or no *B7-1*, *B7-2*, or other costimulatory molecules. Such an interaction would fail to result in T cell expansion, except under conditions of strong TCR ligation.

In the absence of *CTLA-4*, mice develop a rapid and fatal T cell proliferative disease that results in damage to multiple organs (22, 23). If PD-1 ligation provides a checkpoint for T cell activation later in an immune response than *CTLA-4* ligation, this could account for the milder phenotype of *PD-1*-deficient mice compared with *CTLA-4*-deficient mice. Alternatively, the differences in phenotype between mice with these null mutations may reflect differences in the expression patterns of their respective ligands.

The expression patterns of *B7-1*, *B7-2*, and *PD-L1* are distinct. *B7-2*, one of the ligands of CD28 and *CTLA-4*, is constitutively expressed on monocytes; however, constitutive expression of *B7-1* and *B7-2* is not seen in any organ. *B7-1* and *B7-2* expression can be induced in dendritic cells, macrophages, and B cells (15), as well as some types of fibroblast and epithelial cell. In contrast, *PD-L1* is expressed constitutively by nonlymphoid, parenchymal organs such as the heart, placenta, skeletal muscle, and lung, but not the small intestine (16; Fig. 3 D). *PD-L1* is also expressed in some cancers, as three ESTs are from human ovarian tumors. This raises the possibility that some tumors may use *PD-L1* to inhibit an antitumor immune response. We found that *PD-L1* expression by monocytes and keratinocytes was enhanced by stimulation with IFN- γ . Upon activation, keratinocytes express MHC class II, but not *B7-1* or *B7-2* (24). Induction of *PD-L1* expression by cytokines such as IFN- γ or other inflammatory stimuli could result in attenuation of TCR/CD28-mediated T cell activation. This may be of particular significance in the effector sites of inflammatory or autoimmune responses. As *PD-1* is expressed on activated T as well as B cells (2), the expression of *PD-L1* in nonlymphoid tissues as well as on dendritic cells may allow for regulation of potentially autoreactive lymphocytes at sites of immune activation as well as at effector sites. This may be a particularly important mechanism in limiting activities of both T and B cells in the heart, lung, kidney, and placenta where *PD-L1* is highly expressed. In this context, *Fas-L*, a potent immune negative regulator, is also expressed on nonlymphoid tissues including the small intestine and testis (25). Interestingly, the tissue expression patterns of *PD-L1* and *Fas-L* appear to be in general mutually exclusive, suggesting nonredundant regulation of peripheral tolerance by the *Fas*–*Fas-L* and PD-1–PD-L1 pathways.

We thank Ms. M. Yamamoto and Y. Tabuchi for their technical assistance and Ms. K. Saito for her secretarial help. We thank Dr. N. Minato for helpful discussions.

This work was supported by a Center of Excellence grant from the Ministry of Education, Science, Sports, and Culture of Japan, and by National Institutes of Health grants AI39671, AI41584, and CA84500 (to G.J. Freeman).

Submitted: 14 August 2000

Accepted: 24 August 2000

References

- Ishida, Y., Y. Agata, K. Shibahara, and T. Honjo. 1992. In-

- duced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. *EMBO (Eur. Mol. Biol. Organ.) J.* 11:3887–3895.
2. Agata, Y., A. Kawasaki, H. Nishimura, Y. Ishida, T. Tsubata, H. Yagita, and T. Honjo. 1996. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. *Int. Immunol.* 8:765–772.
 3. Vibhakar, R., G. Juan, F. Traganos, Z. Darzynkiewicz, and L.R. Finger. 1997. Activation-induced expression of human programmed death-1 gene in T-lymphocytes. *Exp. Cell Res.* 232:25–28.
 4. Shinohara, T., M. Taniwaki, Y. Ishida, M. Kawaichi, and T. Honjo. 1994. Structure and chromosomal localization of the human PD-1 gene (PDCD1). *Genomics.* 23:704–706.
 5. Vivier, E., and M. Daeron. 1997. Immunoreceptor tyrosine-based inhibition motifs. *Immunol. Today.* 18:286–291.
 6. Nishimura, H., M. Nose, H. Hiai, N. Minato, and T. Honjo. 1999. Development of lupus-like autoimmune diseases by disruption of the *PD-1* gene encoding an ITIM motif-carrying immunoreceptor. *Immunity.* 11:141–151.
 7. Sperling, A.I., and J.A. Bluestone. 1996. The complexities of T-cell costimulation: CD28 and beyond. *Immunol. Rev.* 153: 155–182.
 8. Thompson, C.B., and J.P. Allison. 1997. The emerging role of CTLA-4 as an immune attenuator. *Immunity.* 7:445–450.
 9. Harper, K., C. Balzano, E. Rouvier, M.-G. Mattei, M.F. Luciani, and P. Golstein. 1991. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. *J. Immunol.* 147:1037–1044.
 10. Freeman, G.J., A.A. Cardoso, V.A. Boussiotis, A. Anumathan, R.W. Groves, T.S. Kupper, E.A. Clark, and L.M. Nadler. 1998. The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counter receptor. *J. Immunol.* 161: 2708–2715.
 11. Ling, V., P.W. Wu, H.F. Finnerty, K.M. Bean, V. Spaulding, L.A. Fouser, J.P. Leonard, S.E. Hunter, R. Zollner, J.L. Thomas, et al. 2000. Identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor. *J. Immunol.* 164:1653–1657.
 12. Blair, P.J., J.L. Riley, B.L. Levine, K.P. Lee, N. Craighead, T. Francomano, S.J. Peretto, G.S. Gray, B.M. Carreno, and C.H. June. 1998. CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X_L induction. *J. Immunol.* 160:12–15.
 13. Byrne, M.C., M.Z. Whitley, and M.T. Follettie. 2000. Preparation of mRNA for expression monitoring. In *Current Protocols in Molecular Biology Supplement*. Vol. 49. F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, and K. Struhl, editors. John Wiley & Sons, Inc., New York. 22.2.1–22.2.13.
 14. Freeman, G.J., D.B. Lombard, C.D. Gimmi, S.A. Brod, K. Lee, J.C. Laning, D.A. Hafler, M.E. Dorf, G.S. Gray, H. Reiser, et al. 1992. CTLA-4 and CD28 are coexpressed in most T-cells after activation. *J. Immunol.* 149:3795–3801.
 15. Boussiotis, V.A., G.J. Freeman, J.G. Gribben, and L.M. Nadler. 1996. The role of B7-1/B7-2:CD28/CTLA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. *Immunol. Rev.* 153:5–26.
 16. Dong, H., G. Zhu, K. Tamada, and L. Chen. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. *Nat. Med.* 5:1365–1369.
 17. Swallow, M.M., J.J. Wallin, and W.C. Sha. 1999. B7h, a novel costimulatory homolog of B7-1 and B7-2, is induced by TNF α . *Immunity.* 11:423–432.
 18. Yoshinaga, S.K., J.S. Whoriskey, S.D. Khare, U. Sarmiento, J. Guo, T. Horan, G. Shih, M. Zhang, M.A. Coccia, T. Kohno, et al. 1999. T-cell co-stimulation through B7RP-1 and ICOS. *Nature.* 402:827–832.
 19. Reeves, R.H., D. Patch, A.H. Sharpe, F. Borriello, G.J. Freeman, S. Edelhoff, and C. Disteche. 1997. The costimulatory genes CD80 and CD86 are linked on mouse chromosome 16 and human chromosome 3. *Mamm. Genome.* 8:581–582.
 20. Henry, J., M.M. Miller, and P. Pontarotti. 1999. Structure and evolution of the extended B7 family. *Immunol. Today.* 20:285–288.
 21. Nishimura, H., T. Nakano, N. Minato, and T. Honjo. 1998. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. *Int. Immunol.* 10:1563–1572.
 22. Tivol, E.A., F. Borriello, A.N. Schweitzer, W.P. Lynch, J.A. Bluestone, and A.H. Sharpe. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. *Immunity.* 3:541–547.
 23. Waterhouse, P., J.M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K.P. Lee, C.B. Thompson, H. Griesser, and T.W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. *Science.* 270:985–988.
 24. Nickloff, B.J., R.S. Mitra, K. Lee, L.A. Turka, J. Green, C. Thompson, and Y. Shimizu. 1993. Discordant expression of CD28 ligands, BB-1, and B7-1 on keratinocytes in vitro and psoriatic cells in vivo. *Am. J. Pathology.* 142:1029–1040.
 25. Suda, T., T. Takahashi, P. Golstein, and S. Nagata. 1993. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. *Cell.* 75:1169–1178.
 26. Ikemizu, S., R.J.C. Gilbert, J.A. Fennelly, A.V. Collins, K. Harlos, E.Y. Jones, D.I. Stuart, and S.J. Davis. 2000. Structure and dimerization of a soluble form of B7-1. *Immunity.* 12:51–60.
 27. Fitz, L.J., J.C. Morris, P. Towler, A. Long, P. Burgess, R. Greco, J. Wang, R. Gassaway, E. Nickbarg, S. Kovacic, et al. 1997. Characterization of murine Flt4 ligand/VEGF-C. *Oncogene.* 15:613–618.
 28. Freedman, A.S., G.J. Freeman, K. Rhyhart, and L.M. Nadler. 1991. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. *Cell. Immunol.* 137:429–437.